The effects of statin use on inflammatory markers among patients with metabolic syndrome and related disorders: A systematic review and meta-analysis of randomized controlled trials
[Display omitted] Current evidence suggests that statin use decreases the incidence of cardiovascular diseases (CVD) through reducing LDL cholesterol and decreasing inflammation. Metabolic syndrome (MetS) is usually associated with increased inflammatory markers and increased risk of CVD. We conduct...
Gespeichert in:
| Veröffentlicht in: | Pharmacological research 2019-03, Vol.141, p.85-103 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 103 |
|---|---|
| container_issue | |
| container_start_page | 85 |
| container_title | Pharmacological research |
| container_volume | 141 |
| creator | Tabrizi, Reza Tamtaji, Omid Reza Mirhosseini, Naghmeh Lankarani, Kamran B. Akbari, Maryam Dadgostar, Ehsan Borhani-Haghighi, Afshin Peymani, Payam Ahmadizar, Fariba Asemi, Zatollah |
| description | [Display omitted]
Current evidence suggests that statin use decreases the incidence of cardiovascular diseases (CVD) through reducing LDL cholesterol and decreasing inflammation. Metabolic syndrome (MetS) is usually associated with increased inflammatory markers and increased risk of CVD. We conducted a systematic review and meta-analysis to determine the effect of statin use on inflammatory markers including C-reactive protein (CRP), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and interleukin-1 (IL-1) among patients with MetS and related disorders. PubMed, EMBASE, Web of Science databases, and Cochrane Library were searched for randomized controlled trials (RCTs) through April 2018. Three independent investigators evaluated study eligibilities, extracted data, and assessed study quality using the Cochrane Collaboration risk of bias tool and Jadad's quality scales. Heterogeneity was determined using Cochran’s Q statistic and I-square (I2) test. Based on the heterogeneity results, we pooled data using random-effect or fixed effect models presented as standardized mean differences (SMD) and corresponding 95% confidence intervals (CI). One hundred thirteen RCTs (19,644 patients) were included in our meta-analysis. The pooled results using random effects model showed that statin use statistically significantly decreased CRP level (SMD= -0.97; 95% CI, -1.10, -0.85; P |
| doi_str_mv | 10.1016/j.phrs.2018.12.010 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2159985994</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1043661818313367</els_id><sourcerecordid>2159985994</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-30b62a6f509a7d93963ce66d67a76821c1b2acf1a8a55cdd06688dd875f107683</originalsourceid><addsrcrecordid>eNp9kc1u1DAUhS1ERX_gBVggL9kk2MnEcRCbqoKCVIlNu7Y89g3jwT-D7aEa3qvvx02nsOzCulfWd47scwh5y1nLGRcftu1uk0vbMS5b3rWMsxfkjLNJNJxL8XLZV30jBJen5LyULWNsWnH2ipz2bBjFOMkz8nC7AQrzDKYWmmZaqq4u0n0BmiJ1cfY6BF1TPtCg80_IheqQ4g-6Qw4iiu5d3dAAVa-Td4aWQ7Q5BaA6WprB6wqWWldStij-SC-RKBXQE-EMvx3cP6KLQ6Oj9ofiHl-S8TYF9wflJsWak_e41uy0L6_JyYwD3jzNC3L35fPt1dfm5vv1t6vLm8b0g6hNz9ai02Ie2KRHO_WT6A0IYcWoRyE7bvi602bmWuphMNYyIaS0Vo7DzBkS_QV5f_Td5fRrD6Wq4IoB73WEtC-q48M0STwrRLsjanIqJcOsdtlhZAfFmVrqUlu11KWWuhTvFNaFondP_vt1APtf8q8fBD4dAcBfYlZZFYOxG7AuY2XKJvec_1_RAatz</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2159985994</pqid></control><display><type>article</type><title>The effects of statin use on inflammatory markers among patients with metabolic syndrome and related disorders: A systematic review and meta-analysis of randomized controlled trials</title><source>Elsevier ScienceDirect Journals Complete</source><creator>Tabrizi, Reza ; Tamtaji, Omid Reza ; Mirhosseini, Naghmeh ; Lankarani, Kamran B. ; Akbari, Maryam ; Dadgostar, Ehsan ; Borhani-Haghighi, Afshin ; Peymani, Payam ; Ahmadizar, Fariba ; Asemi, Zatollah</creator><creatorcontrib>Tabrizi, Reza ; Tamtaji, Omid Reza ; Mirhosseini, Naghmeh ; Lankarani, Kamran B. ; Akbari, Maryam ; Dadgostar, Ehsan ; Borhani-Haghighi, Afshin ; Peymani, Payam ; Ahmadizar, Fariba ; Asemi, Zatollah</creatorcontrib><description>[Display omitted]
Current evidence suggests that statin use decreases the incidence of cardiovascular diseases (CVD) through reducing LDL cholesterol and decreasing inflammation. Metabolic syndrome (MetS) is usually associated with increased inflammatory markers and increased risk of CVD. We conducted a systematic review and meta-analysis to determine the effect of statin use on inflammatory markers including C-reactive protein (CRP), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and interleukin-1 (IL-1) among patients with MetS and related disorders. PubMed, EMBASE, Web of Science databases, and Cochrane Library were searched for randomized controlled trials (RCTs) through April 2018. Three independent investigators evaluated study eligibilities, extracted data, and assessed study quality using the Cochrane Collaboration risk of bias tool and Jadad's quality scales. Heterogeneity was determined using Cochran’s Q statistic and I-square (I2) test. Based on the heterogeneity results, we pooled data using random-effect or fixed effect models presented as standardized mean differences (SMD) and corresponding 95% confidence intervals (CI). One hundred thirteen RCTs (19,644 patients) were included in our meta-analysis. The pooled results using random effects model showed that statin use statistically significantly decreased CRP level (SMD= -0.97; 95% CI, -1.10, -0.85; P < 0.001; I2: 95.1%), TNF-α (SMD= -1.88; 95% CI, -2.40, -1.38; P < 0.001; I2: 97.2%), IL-6 (SMD= -1.67; 95% CI, -1.98, -1.34; P < 0.001; I2: 96.5%), and IL-1 concentrations (SMD= -8.35; 95% CI, -10.49, -6.22; P < 0.001; I2: 98.4%) among patients with MetS and related disorders. Our meta-analysis showed beneficial effects of statin use on reducing inflammatory markers in patients with MetS and related disorders.</description><identifier>ISSN: 1043-6618</identifier><identifier>EISSN: 1096-1186</identifier><identifier>DOI: 10.1016/j.phrs.2018.12.010</identifier><identifier>PMID: 30576798</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Inflammatory markers ; Meta-analysis ; Metabolic syndrome ; Randomized control trial ; Statin use</subject><ispartof>Pharmacological research, 2019-03, Vol.141, p.85-103</ispartof><rights>2018 Elsevier Ltd</rights><rights>Copyright © 2018 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-30b62a6f509a7d93963ce66d67a76821c1b2acf1a8a55cdd06688dd875f107683</citedby><cites>FETCH-LOGICAL-c356t-30b62a6f509a7d93963ce66d67a76821c1b2acf1a8a55cdd06688dd875f107683</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1043661818313367$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30576798$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tabrizi, Reza</creatorcontrib><creatorcontrib>Tamtaji, Omid Reza</creatorcontrib><creatorcontrib>Mirhosseini, Naghmeh</creatorcontrib><creatorcontrib>Lankarani, Kamran B.</creatorcontrib><creatorcontrib>Akbari, Maryam</creatorcontrib><creatorcontrib>Dadgostar, Ehsan</creatorcontrib><creatorcontrib>Borhani-Haghighi, Afshin</creatorcontrib><creatorcontrib>Peymani, Payam</creatorcontrib><creatorcontrib>Ahmadizar, Fariba</creatorcontrib><creatorcontrib>Asemi, Zatollah</creatorcontrib><title>The effects of statin use on inflammatory markers among patients with metabolic syndrome and related disorders: A systematic review and meta-analysis of randomized controlled trials</title><title>Pharmacological research</title><addtitle>Pharmacol Res</addtitle><description>[Display omitted]
Current evidence suggests that statin use decreases the incidence of cardiovascular diseases (CVD) through reducing LDL cholesterol and decreasing inflammation. Metabolic syndrome (MetS) is usually associated with increased inflammatory markers and increased risk of CVD. We conducted a systematic review and meta-analysis to determine the effect of statin use on inflammatory markers including C-reactive protein (CRP), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and interleukin-1 (IL-1) among patients with MetS and related disorders. PubMed, EMBASE, Web of Science databases, and Cochrane Library were searched for randomized controlled trials (RCTs) through April 2018. Three independent investigators evaluated study eligibilities, extracted data, and assessed study quality using the Cochrane Collaboration risk of bias tool and Jadad's quality scales. Heterogeneity was determined using Cochran’s Q statistic and I-square (I2) test. Based on the heterogeneity results, we pooled data using random-effect or fixed effect models presented as standardized mean differences (SMD) and corresponding 95% confidence intervals (CI). One hundred thirteen RCTs (19,644 patients) were included in our meta-analysis. The pooled results using random effects model showed that statin use statistically significantly decreased CRP level (SMD= -0.97; 95% CI, -1.10, -0.85; P < 0.001; I2: 95.1%), TNF-α (SMD= -1.88; 95% CI, -2.40, -1.38; P < 0.001; I2: 97.2%), IL-6 (SMD= -1.67; 95% CI, -1.98, -1.34; P < 0.001; I2: 96.5%), and IL-1 concentrations (SMD= -8.35; 95% CI, -10.49, -6.22; P < 0.001; I2: 98.4%) among patients with MetS and related disorders. Our meta-analysis showed beneficial effects of statin use on reducing inflammatory markers in patients with MetS and related disorders.</description><subject>Inflammatory markers</subject><subject>Meta-analysis</subject><subject>Metabolic syndrome</subject><subject>Randomized control trial</subject><subject>Statin use</subject><issn>1043-6618</issn><issn>1096-1186</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp9kc1u1DAUhS1ERX_gBVggL9kk2MnEcRCbqoKCVIlNu7Y89g3jwT-D7aEa3qvvx02nsOzCulfWd47scwh5y1nLGRcftu1uk0vbMS5b3rWMsxfkjLNJNJxL8XLZV30jBJen5LyULWNsWnH2ipz2bBjFOMkz8nC7AQrzDKYWmmZaqq4u0n0BmiJ1cfY6BF1TPtCg80_IheqQ4g-6Qw4iiu5d3dAAVa-Td4aWQ7Q5BaA6WprB6wqWWldStij-SC-RKBXQE-EMvx3cP6KLQ6Oj9ofiHl-S8TYF9wflJsWak_e41uy0L6_JyYwD3jzNC3L35fPt1dfm5vv1t6vLm8b0g6hNz9ai02Ie2KRHO_WT6A0IYcWoRyE7bvi602bmWuphMNYyIaS0Vo7DzBkS_QV5f_Td5fRrD6Wq4IoB73WEtC-q48M0STwrRLsjanIqJcOsdtlhZAfFmVrqUlu11KWWuhTvFNaFondP_vt1APtf8q8fBD4dAcBfYlZZFYOxG7AuY2XKJvec_1_RAatz</recordid><startdate>20190301</startdate><enddate>20190301</enddate><creator>Tabrizi, Reza</creator><creator>Tamtaji, Omid Reza</creator><creator>Mirhosseini, Naghmeh</creator><creator>Lankarani, Kamran B.</creator><creator>Akbari, Maryam</creator><creator>Dadgostar, Ehsan</creator><creator>Borhani-Haghighi, Afshin</creator><creator>Peymani, Payam</creator><creator>Ahmadizar, Fariba</creator><creator>Asemi, Zatollah</creator><general>Elsevier Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20190301</creationdate><title>The effects of statin use on inflammatory markers among patients with metabolic syndrome and related disorders: A systematic review and meta-analysis of randomized controlled trials</title><author>Tabrizi, Reza ; Tamtaji, Omid Reza ; Mirhosseini, Naghmeh ; Lankarani, Kamran B. ; Akbari, Maryam ; Dadgostar, Ehsan ; Borhani-Haghighi, Afshin ; Peymani, Payam ; Ahmadizar, Fariba ; Asemi, Zatollah</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-30b62a6f509a7d93963ce66d67a76821c1b2acf1a8a55cdd06688dd875f107683</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Inflammatory markers</topic><topic>Meta-analysis</topic><topic>Metabolic syndrome</topic><topic>Randomized control trial</topic><topic>Statin use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tabrizi, Reza</creatorcontrib><creatorcontrib>Tamtaji, Omid Reza</creatorcontrib><creatorcontrib>Mirhosseini, Naghmeh</creatorcontrib><creatorcontrib>Lankarani, Kamran B.</creatorcontrib><creatorcontrib>Akbari, Maryam</creatorcontrib><creatorcontrib>Dadgostar, Ehsan</creatorcontrib><creatorcontrib>Borhani-Haghighi, Afshin</creatorcontrib><creatorcontrib>Peymani, Payam</creatorcontrib><creatorcontrib>Ahmadizar, Fariba</creatorcontrib><creatorcontrib>Asemi, Zatollah</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Pharmacological research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tabrizi, Reza</au><au>Tamtaji, Omid Reza</au><au>Mirhosseini, Naghmeh</au><au>Lankarani, Kamran B.</au><au>Akbari, Maryam</au><au>Dadgostar, Ehsan</au><au>Borhani-Haghighi, Afshin</au><au>Peymani, Payam</au><au>Ahmadizar, Fariba</au><au>Asemi, Zatollah</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The effects of statin use on inflammatory markers among patients with metabolic syndrome and related disorders: A systematic review and meta-analysis of randomized controlled trials</atitle><jtitle>Pharmacological research</jtitle><addtitle>Pharmacol Res</addtitle><date>2019-03-01</date><risdate>2019</risdate><volume>141</volume><spage>85</spage><epage>103</epage><pages>85-103</pages><issn>1043-6618</issn><eissn>1096-1186</eissn><abstract>[Display omitted]
Current evidence suggests that statin use decreases the incidence of cardiovascular diseases (CVD) through reducing LDL cholesterol and decreasing inflammation. Metabolic syndrome (MetS) is usually associated with increased inflammatory markers and increased risk of CVD. We conducted a systematic review and meta-analysis to determine the effect of statin use on inflammatory markers including C-reactive protein (CRP), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and interleukin-1 (IL-1) among patients with MetS and related disorders. PubMed, EMBASE, Web of Science databases, and Cochrane Library were searched for randomized controlled trials (RCTs) through April 2018. Three independent investigators evaluated study eligibilities, extracted data, and assessed study quality using the Cochrane Collaboration risk of bias tool and Jadad's quality scales. Heterogeneity was determined using Cochran’s Q statistic and I-square (I2) test. Based on the heterogeneity results, we pooled data using random-effect or fixed effect models presented as standardized mean differences (SMD) and corresponding 95% confidence intervals (CI). One hundred thirteen RCTs (19,644 patients) were included in our meta-analysis. The pooled results using random effects model showed that statin use statistically significantly decreased CRP level (SMD= -0.97; 95% CI, -1.10, -0.85; P < 0.001; I2: 95.1%), TNF-α (SMD= -1.88; 95% CI, -2.40, -1.38; P < 0.001; I2: 97.2%), IL-6 (SMD= -1.67; 95% CI, -1.98, -1.34; P < 0.001; I2: 96.5%), and IL-1 concentrations (SMD= -8.35; 95% CI, -10.49, -6.22; P < 0.001; I2: 98.4%) among patients with MetS and related disorders. Our meta-analysis showed beneficial effects of statin use on reducing inflammatory markers in patients with MetS and related disorders.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>30576798</pmid><doi>10.1016/j.phrs.2018.12.010</doi><tpages>19</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1043-6618 |
| ispartof | Pharmacological research, 2019-03, Vol.141, p.85-103 |
| issn | 1043-6618 1096-1186 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2159985994 |
| source | Elsevier ScienceDirect Journals Complete |
| subjects | Inflammatory markers Meta-analysis Metabolic syndrome Randomized control trial Statin use |
| title | The effects of statin use on inflammatory markers among patients with metabolic syndrome and related disorders: A systematic review and meta-analysis of randomized controlled trials |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T21%3A22%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20effects%20of%20statin%20use%20on%20inflammatory%20markers%20among%20patients%20with%20metabolic%20syndrome%20and%20related%20disorders:%20A%20systematic%20review%20and%20meta-analysis%20of%20randomized%20controlled%20trials&rft.jtitle=Pharmacological%20research&rft.au=Tabrizi,%20Reza&rft.date=2019-03-01&rft.volume=141&rft.spage=85&rft.epage=103&rft.pages=85-103&rft.issn=1043-6618&rft.eissn=1096-1186&rft_id=info:doi/10.1016/j.phrs.2018.12.010&rft_dat=%3Cproquest_cross%3E2159985994%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2159985994&rft_id=info:pmid/30576798&rft_els_id=S1043661818313367&rfr_iscdi=true |